|Dr. Jean-Pierre Sommadossi Ph.D.||Founder, Chairman, CEO & Pres||902.99k||N/A||1956|
|Dr. Janet M.J. Hammond||Chief Devel. Officer||728.32k||N/A||1960|
|Dr. Maria Arantxa Horga M.D.||Chief Medical Officer||367.56k||N/A||1968|
|Ms. Andrea J. Corcoran||CFO, Exec. VP of Legal & Sec.||N/A||N/A||1962|
|Mr. Wayne Foster CPA, CPA||Sr. VP of Fin. & Admin.||N/A||N/A||1968|
|Ms. Jonae R. Barnes||Sr. VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Paul J. Fanning||Sr. VP of HR||N/A||N/A||1958|
|Mr. Steven Good||Exec. VP of Preclinical Science||N/A||N/A||N/A|
|Mr. Adel Moussa Ph.D.||Exec. VP of Chemistry||N/A||N/A||N/A|
|Mr. Xiao-Jian Zhou Ph.D.||Exec. VP of Early Stage Devel.||N/A||N/A||N/A|
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Atea Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 9. The pillar scores are Audit: 6; Board: 8; Shareholder Rights: 8; Compensation: 9.